RGNX 📈 Regenxbio - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75901B1070
RGNX: Gene, Therapies, Virus, Vector, Delivery, Platform
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Web URL: https://www.regenxbio.com
Additional Sources for RGNX Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RGNX Stock Overview
| Market Cap in USD | 390m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2015-09-17 |
RGNX Stock Ratings
| Growth 5y | -95.0% |
| Fundamental | -45.0% |
| Dividend | - |
| Rel. Strength Industry | -2494 |
| Analysts | 4.55/5 |
| Fair Price Momentum | 4.60 USD |
| Fair Price DCF | - |
RGNX Dividends
No Dividends PaidRGNX Growth Ratios
| Growth Correlation 3m | -50% |
| Growth Correlation 12m | -85.3% |
| Growth Correlation 5y | -90.6% |
| CAGR 5y | -28.78% |
| CAGR/Mean DD 5y | -0.57 |
| Sharpe Ratio 12m | -0.93 |
| Alpha | -94.49 |
| Beta | 1.40 |
| Volatility | 79.08% |
| Current Volume | 1272.1k |
| Average Volume 20d | 1781.3k |
What is the price of RGNX stocks?
As of December 30, 2024, the stock is trading at USD 7.41 with a total of 1,272,112 shares traded.
Over the past week, the price has changed by +0.41%, over one month by -25.30%, over three months by -29.36% and over the past year by -58.72%.
As of December 30, 2024, the stock is trading at USD 7.41 with a total of 1,272,112 shares traded.
Over the past week, the price has changed by +0.41%, over one month by -25.30%, over three months by -29.36% and over the past year by -58.72%.
Is Regenxbio a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Regenxbio (NASDAQ:RGNX) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.99 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RGNX as of December 2024 is 4.60. This means that RGNX is currently overvalued and has a potential downside of -37.92%.
Probably not. Based on ValueRay Fundamental Analyses, Regenxbio (NASDAQ:RGNX) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.99 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RGNX as of December 2024 is 4.60. This means that RGNX is currently overvalued and has a potential downside of -37.92%.
Is RGNX a buy, sell or hold?
Regenxbio has received a consensus analysts rating of 4.55. Therefor, it is recommend to buy RGNX.
Regenxbio has received a consensus analysts rating of 4.55. Therefor, it is recommend to buy RGNX.
- Strong Buy: 6
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for RGNX stock price target?
According to ValueRays Forecast Model, RGNX Regenxbio will be worth about 5.1 in December 2025. The stock is currently trading at 7.41. This means that the stock has a potential downside of -30.9%.
According to ValueRays Forecast Model, RGNX Regenxbio will be worth about 5.1 in December 2025. The stock is currently trading at 7.41. This means that the stock has a potential downside of -30.9%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 37.6 | 408% |
| Analysts Target Price | 41.6 | 460.7% |
| ValueRay Target Price | 5.1 | -30.9% |